1415 related articles for article (PubMed ID: 22212568)
1. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
3. Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir for untreated chronic HCV genotype 1 infection.
Poordad F; McCone J; Bacon BR; Bruno S; Manns MP; Sulkowski MS; Jacobson IM; Reddy KR; Goodman ZD; Boparai N; DiNubile MJ; Sniukiene V; Brass CA; Albrecht JK; Bronowicki JP;
N Engl J Med; 2011 Mar; 364(13):1195-206. PubMed ID: 21449783
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Forestier N; Zeuzem S
Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Sitole M; Silva M; Spooner L; Comee MK; Malloy M
Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS; Spooner LM; Belliveau PP
Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
14. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Poordad F; Lawitz E; Reddy KR; Afdhal NH; Hézode C; Zeuzem S; Lee SS; Calleja JL; Brown RS; Craxi A; Wedemeyer H; Nyberg L; Nelson DR; Rossaro L; Balart L; Morgan TR; Bacon BR; Flamm SL; Kowdley KV; Deng W; Koury KJ; Pedicone LD; Dutko FJ; Burroughs MH; Alves K; Wahl J; Brass CA; Albrecht JK; Sulkowski MS;
Gastroenterology; 2013 Nov; 145(5):1035-1044.e5. PubMed ID: 23924660
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Bacon BR; Khalid O
Liver Int; 2012 Feb; 32 Suppl 1():51-3. PubMed ID: 22212572
[TBL] [Abstract][Full Text] [Related]
16. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Shiffman ML; Esteban R
Liver Int; 2012 Feb; 32 Suppl 1():54-60. PubMed ID: 22212573
[TBL] [Abstract][Full Text] [Related]
18. Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Kwo PY
Liver Int; 2012 Feb; 32 Suppl 1():39-43. PubMed ID: 22212570
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment with boceprevir for chronic HCV infection.
Maasoumy B; Manns MP
Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841
[TBL] [Abstract][Full Text] [Related]
20. How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Bourlière M; Wendt A; Fontaine H; Hézode C; Pol S; Bronowicki JP
Liver Int; 2013 Feb; 33 Suppl 1():46-55. PubMed ID: 23286846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
